SAR446268

PreclinicalBiologic

Sanofi

SAR446268 is one of 3 biologic programs targeting Myotonic Dystrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myotonic DystrophyRecruiting

Myotonic DystrophyPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Myotonic Dystrophy

#DrugCompanyPhaseTrials

Mexitil

Boehringer Ingelheim

Approved

1 2

Tideglusib

AAMO Pharma Limited

Phase 3

4 3

SAR446268

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

PreclinicalRecruiting

Myotonic Dystrophy

NCT06844214

Clinical

Trials by Indication[1]

Myotonic Dystrophy1 trial

A Phase 1/Phase 2 Open-label Single Arm Study With Dose Escalation (Part A), and Dose Expansion (Part B) Parts to Evaluate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants 10 to 55 Years Old With Non-congenital Myotonic Dystrophy Type 1

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT06844214·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SAR446268. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR446268 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR446268. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Sanofi

SAR446268

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Myotonic Dystrophy1 trial

References

Drug Info

Quick Facts

Related News